Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Medarex Announces Primary Endpoint Achieved In MDX-1100 Anti-IP-10 Antibody Phase 2 Trial For Rheumatoid Arthritis
Medarex, Inc. (Nasdaq: MEDX) announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate successfully met its primary endpoint. The top-line results from the recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated that when compared to placebo, three times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks, the primary endpoint of the study, as measured by the American College of Rheumatology (ACR) 20 measurement of response. These results were statistically significant when compared with placebo (p=0.0024). The antibody combination with methotrexate was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.
generic viagra online
Online Training For GP Teams Focuses On Care Plans For People With Intellectual Disability
The Royal Australian College of General Practitioners (RACGP) has released a new online learning activity designed to support general practitioners and other members of the general practice team in developing high quality care plans for people with intellectual disability, and in understanding eligibility requirements for Medicare-funded care plans.
News of the day
Antibody Surrogates Are Just A 'Click' Away, Caltech Chemists Say
Chemists at the California Institute of Technology (Caltech) and the Scripps Research Institute have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests.
Diagnostics

Prehypertension, Obesity And Kidney Disease Risks

People with prehypertension are not at increased risk of kidney disease if their body mass index (BMI) is under 30.0 kg/m2, a first-ever examination of the combined effect of blood pressure and body weight on the risk of kidney disease shows. The study, by a team of medical researchers at the Norwegian University of Science and Technology (NTNU) is available as a pre-publication article online from the American Journal of Kidney Diseases. Prehypertension is a relatively new medical classification introduced in 2003 in the Seventh Report of the Joint National Committee on High Blood Pressure (JNC-7), and is defined as systolic blood pressure of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg. Studies from the United States and Asia have shown that prehypertension can increase the risk of serious kidney disease, but because more than 30 percent of the US and European populations can be classified as prehypertensive, treating everyone with this condition would be an enormous undertaking, the researchers observed. At the same time, obesity is also known to lead to end-stage renal disease (ESRD) and death from chronic kidney disease (CKD) as a result of diabetes and hypertension. These increased risks have led medical researchers to consider whether people with prehypertension should be considered for treatment if they have other cardiovascular risks, such as obesity. Using data from nearly 75,000 participants in the HUNT 1 study, the first Health Study in Nord-TrÃñndelag, a team of NTNU researchers led by Dr. John Munkhaugen were able to further clarify the risks of ESRD in overweight individuals. "We found a strong, independent and continuous association with both BP and body weight" on the risk of treated ESRD or chronic kidney disease related deaths, the researchers wrote. However, "prehypertensive participants increased their risk of treated ESRD or CKD-related death only if BMI was greater than 30.0 kg/m2." The strength of the NTNU study is its ability to use data from the two-decade old HUNT 1 study, which provides researchers the ability to follow up on measurements made 20 years ago. The HUNT 1 study involved 88.2 percent of all inhabitants 20 years or older in Nord-TrÃñndelag county, in mid-Norway. The data were linked to the Norwegian Renal Registry and to the Cause of Death Registry in Norway. NTNU


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009